Evidence map›Paper›PMID 40950013›Full record

ArticlebioRxiv : the preprint server for biology2025

A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage.

Matthew J Moeser, Olivia D Council, Nathan Long, Laura Kincer, Ann M Dennis, Joseph Eron, David Wohl, Claire E Farel, Julie Nelson, Abbas Mohammadi and 10 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Matthew J MoeserDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Olivia D CouncilDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nathan LongDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Laura KincerDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Ann M DennisDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, NC, USA.
Joseph EronDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, NC, USA.
David WohlDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, NC, USA.
Claire E FarelDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, NC, USA.
Julie NelsonDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abbas MohammadiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Behzad EtemadBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan Z LiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Hugh McGannWaikato Hospital, Hamilton, NZ.
Erasmus SmitWaikato Hospital, Hamilton, NZ.
Meredith ClementLSU Health Sciences Center, New Orleans, LA, USA.
Tat YauLSU Health Sciences Center, New Orleans, LA, USA.
Prema MenezesUniversity of North Carolina Center for AIDS Research.
Natalie M BowmanDivision of Infectious Diseases, School of Medicine, University of North Carolina at Chapel Hill, NC, USA.
Shuntai ZhouDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sarah B JosephDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2021 to 2026
$31.6M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Ya-Chi Ho, Jonathan Li · 2022 to 2026
$10.1M
Identifying Roadblocks to Antigen Expression and Enhancing Killing of HIV-Infected Cells That Are Refractory to ClearanceR01AI176596 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nancie Marie Archin, SARAH BETH JOSEPH · 2023 to 2026
$4.6M
Development and Use of Novel SHIVs Bearing Clinically Relevant HIV-1 Envs for Examining HIV Persistence and Eradication in the CNS of Nonhuman PrimatesR01MH118990 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH, SARAH BETH · 2019 to 2023
$3.2M
NIAID NIH HHS P01 AI169768NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI176596NIAID NIH HHS UM1 AI164567NIMH NIH HHS R01 MH118990
6 · The paper itself

Abstract

Background: HIV-1 RNA typically declines rapidly after initiation of antiretroviral therapy (ART); often reaching undetectable levels within a few weeks and remaining undetectable by standard assays. However, some patients on ART have persistent nonsuppressible viremia (NSV) that does not respond to treatment optimization or intensification. NSV can emerge at the time of ART initiation ( Methods: Blood samples were collected from four participants who, despite being adherent to ART, required approximately a year or more to become virologically suppressed. Viral RNA and proviral DNA genomes were sequenced to examine HIV-1 drug resistance, genome intactness and genetic diversity. The ability of HIV-1 Envs to facilitate efficient entry into cells expressing low levels of CD4 (a proxy for macrophage tropism) was assessed. Results: Before ART, the blood contained HIV-1 RNA genomes that were adapted to replication in CD4+ T cells and rapidly decayed after ART initiation. During ART, the blood contained HIV-1 genomes that were drug sensitive, genetically diverse, macrophage-tropic, not evolving and often had defects in Conclusions: Our results suggest that in individuals with

Identifiers

PMID40950013
PMCPMC12424842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.